- Home
- MREO
as of 12-03-2025 3:59pm EST
$1.95
+$0.20
+11.49%
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Chart Type:
Time Range:
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 286.4M | IPO Year: | N/A |
| Target Price: | $7.40 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.47 - $3.94 | Next Earning Date: | 11-10-2025 |
| Revenue: | $500,000 | Revenue Growth: | -50.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 131.12% |
AI-Powered MREO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 21 hours ago
AI Recommendation
hold
Model Accuracy: 71.81%
71.81%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Mereo BioPharma Group plc News
MREO Breaking Stock News: Dive into MREO Ticker-Specific Updates for Smart Investing
MT Newswires
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading
📊
AI Sentiment
Positive
7/10
Compare MREO vs Leading Stocks
See how MREO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MREO Mereo BioPharma Group plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.